Multicenter Uveitis Steroid Treatment (MUST) Trial
ID Number 07-0276Principal Investigator(s)
Department(s) or Division(s)
The Multicenter Uveitis Steroid Treatment (MUST) Trial is proposed, which will compare the fluocinoline acetonide implant to “standard therapy” for the treatment of patients with severe, vision-threatening intermediate, posterior, or panuveitis. Patients with active uveitis will be randomized to treatment with either the fluocinoline acetonide implant or “standard therapy” consisting of oral corticosteroids and supplementary immunosuppresive drugs when indicated, according to standardized guidelines. This study does not enroll patients at Mount Sinai School of Medicine.
Recruiting Patients: Yes